Advertisement
Screener

PFIZER INC (PFE) Overview

PFIZER INC (PFE) Overview

  • 30 Mar 2026: Period ending 28 Jun 2026; Estimate (m); Actual -0.04; Beat / miss (m).
  • 1 Jan 2026: Period ending 29 Mar 2026; Estimate (m); Actual 0.47; Beat / miss (m).
  • 30 Jun 2025: Period ending 28 Sept 2025; Estimate (m); Actual 0.62; Beat / miss (m).
  • 31 Mar 2025: Period ending 29 Jun 2025; Estimate (m); Actual 0.51; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$22.49$24.22$26.09$28.10$30.27$32.612025-11-062026-11-06$20.51$25.78$32.40$40.72$51.17$64.312021-11-082026-11-06$20.51$26.82$35.07$45.87$59.98$78.432016-11-072026-11-06$10.51$16.68$26.48$42.03$66.72$105.912009-01-022026-11-06$10.51$16.68$26.48$42.03$66.72$105.912009-01-022026-11-06

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$29.39
Previous close
$28.72
Change
$0.67
Change (%)
2.32%
Close date
2026-11-06
Previous close date
2026-09-29
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

PFE
+21.29%
S&P 500
(m)

1 year

PFE
+28.86%
S&P 500
(m)

3 years

PFE
+5.01%
S&P 500
(m)

5 years

PFE
-14.04%
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

28 Jun 2026 ○ Estimate (m) ● Actual -0.04

-0.120.110.340.570.8030 Mar 2025: estimate (m); actual 0.5230 Mar 2025(m)29 Jun 2025: estimate (m); actual 0.5129 Jun 2025(m)28 Sept 2025: estimate (m); actual 0.6228 Sept 2025(m)29 Mar 2026: estimate (m); actual 0.4729 Mar 2026(m)28 Jun 2026: estimate (m); actual -0.0428 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
30 Mar 202628 Jun 2026(m)-0.04(m)(m)
1 Jan 202629 Mar 2026(m)0.47(m)(m)
30 Jun 202528 Sept 2025(m)0.62(m)(m)
31 Mar 202529 Jun 2025(m)0.51(m)(m)
1 Jan 202530 Mar 2025(m)0.52(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual 1.36

0.291.632.974.315.6531 Dec 2021: estimate (m); actual 3.8531 Dec 2021(m)31 Dec 2022: estimate (m); actual 5.4731 Dec 2022(m)31 Dec 2023: estimate (m); actual 0.3731 Dec 2023(m)31 Dec 2024: estimate (m); actual 1.4131 Dec 2024(m)31 Dec 2025: estimate (m); actual 1.3631 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)1.36(m)(m)
1 Jan 202431 Dec 2024(m)1.41(m)(m)
1 Jan 202331 Dec 2023(m)0.37(m)(m)
1 Jan 202231 Dec 2022(m)5.47(m)(m)
1 Jan 202131 Dec 2021(m)3.85(m)(m)

Revenue vs. Earnings

USD

28 Jun 2026 ■ Revenue 15.03B ■ Earnings -0.25B — Profit margin -1.65%

-3.95B-10.4%3.99B0.5%11.92B11.4%19.86B22.3%28 Sept 2025: revenue 16.65B; earnings 3.54B; profit margin 21.26%28 Sept 202531 Dec 2025: revenue 17.56B*; earnings -1.65B*; profit margin -9.39%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-09-29 to 2025-12-31; USD.31 Dec 202529 Mar 2026: revenue 14.45B; earnings 2.69B; profit margin 18.59%29 Mar 202628 Jun 2026: revenue 15.03B; earnings -0.25B; profit margin -1.65%28 Jun 2026

31 Dec 2025 ■ Revenue 62.58B ■ Earnings 7.77B — Profit margin 12.42%

-11.02B3.2%26.93B13.8%64.87B24.5%102.81B35.2%31 Dec 2022: revenue 91.79B; earnings 31.37B; profit margin 34.18%31 Dec 202231 Dec 2023: revenue 50.91B; earnings 2.12B; profit margin 4.16%31 Dec 202331 Dec 2024: revenue 63.63B; earnings 8.03B; profit margin 12.62%31 Dec 202431 Dec 2025: revenue 62.58B; earnings 7.77B; profit margin 12.42%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$29.39(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$29.39High(m)Average(m)Low(m)2025-11-062026-11-06

Recent news

View more →

(m)

YouTube videos mentioning PFE

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 28 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$4.33B
Profit margin
6.80%
Return on assets · 12 month
2.13%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
75.00K
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
32.86M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
2.83%*
Total return · month
2.72%*
Total return · quarter
19.91%*
Total return · half year
9.85%*
Total return · year to date
21.29%*
Total return · 1 year
28.86%*
Total return · 3 years
5.01%*
Total return · 5 years
-14.04%*
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$63.70B
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
74.07%*
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

PFIZER INC Overview

View more →

(m)

(m)

SEC CIK
78003
Industry (SIC)
2834 Pharmaceutical Preparations
Country of operation
United States
Business address
66 HUDSON BOULEVARD EAST, NEW YORK, New York, 10001-2192, United States
Fiscal year end
1231
Phone
2127332323

Similar stocks

Stock NameCountryMarket CapPE Ratio
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64